Organization
Shanxi Provincial People’s Hospital, Xi'an, China
1 abstract
Abstract
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,